HomeAboutRankingsData Sources
© 2026 GeneE
🧬
GeneE
25 sources retrieved · Most recent: April 2026 · Index updated 14 days ago
ⓘGeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
PRKAB1
protein kinase AMP-activated non-catalytic subunit beta 1
Chromosome 12 · 12q24.23
NCBI Gene: 5564Ensembl: ENSG00000111725.11HGNC: HGNC:9378UniProt: Q9Y478
199PubMed Papers
20Diseases
1Drugs
0Pathogenic Variants
RESEARCH IMPACT
Trending
CLINICAL
FDA Approved Target
DATA QUALITY
✓ Experimental GO Evidence✓ Swiss-Prot Reviewed
cellular response to nutrient levelsnucleusprotein bindingpositive regulation of cold-induced thermogenesisneurodegenerative diseaseinflammatory bowel diseasecardiovascular diseaseAlzheimer disease
✦AI Summary

PRKAB1 encodes the non-catalytic beta-1 regulatory subunit of AMP-activated protein kinase (AMPK), a critical cellular energy sensor. PRKAB1 functions as a scaffold protein that assembles the AMPK complex by bridging the catalytic alpha subunits and regulatory gamma subunits, enabling AMPK's core metabolic functions 1. Upon detection of reduced intracellular ATP, AMPK phosphorylates metabolic enzymes and transcription factors to activate energy-producing pathways while inhibiting energy-consuming biosynthetic processes and cell proliferation. PRKAB1 also facilitates cytoskeletal remodeling through myosin regulation and controls mitochondrial dynamics during cell migration 2. Recent studies reveal tissue-specific and isoform-specific roles: PRKAB1 exhibits differential functions compared to PRKAB2 in cardiac lineage specification of stem cells, with PRKAB1 affecting late-stage cardiomyocyte maturation 3. PRKAB1 demonstrates therapeutic relevance in metabolic diseases; buddleoside ameliorates nonalcoholic steatohepatitis (NASH) by directly binding PRKAB1 residues (Val81, Arg83, Ser108) and activating AMPK to enhance autophagy 1, while schisanhenol improves nonalcoholic fatty liver disease through miR-802/PRKAB1-mediated AMPK pathway activation 4. Additionally, PRKAB1 participates in inflammatory bowel disease pathogenesis through host-microbiota interactions 5, and metformin-induced sarcopenia involves PRKAB1 as a drug target 6. These findings establish PRKAB1 as a multifunctional metabolic hub with significant therapeutic potential.

Sources cited
1
PRKAB1 is the scaffold subunit of AMPK complex; buddleoside binds PRKAB1 residues (Val81, Arg83, Ser108) to activate AMPK and ameliorate NASH
PMID: 39936600
2
AMPK controls mitochondrial dynamics and cytoskeletal remodeling during cell migration by regulating myosin phosphatase
PMID: 37217519
3
PRKAB1 and PRKAB2 have isoform-specific functions; PRKAB1 loss impairs late-stage cardiomyocyte differentiation while PRKAB2 is essential for mesoderm specification
PMID: 33454005
4
miR-802 inhibits hepatic AMPK expression by binding to the 3' UTR of PRKAB1; schisanhenol improves NAFLD through the miR-802/AMPK pathway
PMID: 39309511
5
PRKAB1 is involved in gene-microbiota interactions in Crohn's disease through eQTL-mbQTL colocalization
PMID: 37170220
6
PRKAB1 is identified as a primary drug target gene for metformin in association with sarcopenia
PMID: 39511635
Disease Associationsⓘ20
neurodegenerative diseaseOpen Targets
0.48Moderate
inflammatory bowel diseaseOpen Targets
0.38Weak
cardiovascular diseaseOpen Targets
0.38Weak
Alzheimer diseaseOpen Targets
0.37Weak
Parkinson diseaseOpen Targets
0.36Weak
multiple sclerosisOpen Targets
0.35Weak
lysosomal storage diseaseOpen Targets
0.34Weak
HypercholesterolemiaOpen Targets
0.31Weak
hyperlipidemiaOpen Targets
0.28Weak
metabolic diseaseOpen Targets
0.27Weak
neoplasmOpen Targets
0.12Weak
cancerOpen Targets
0.12Weak
hepatocellular carcinomaOpen Targets
0.12Weak
breast cancerOpen Targets
0.11Weak
ovarian cancerOpen Targets
0.11Weak
non-small cell lung carcinomaOpen Targets
0.11Weak
acute myeloid leukemiaOpen Targets
0.11Weak
non-alcoholic fatty liver diseaseOpen Targets
0.11Weak
glioblastoma multiformeOpen Targets
0.11Weak
Huntington diseaseOpen Targets
0.11Weak
Pathogenic Variants
No pathogenic variants reported on ClinVar for this gene.
View on ClinVar ↗
Drug Targets1
ACADESINEApproved
AMP-activated protein kinase, AMPK activator
cardiovascular disease
Related Genes
CAB39Protein interaction100%TSC1Protein interaction100%ACACAProtein interaction100%ACACBProtein interaction100%ELAVL1Protein interaction100%GYS1Protein interaction100%
Tissue Expression6 tissues
Bone Marrow
100%
Lung
56%
Liver
42%
Brain
40%
Ovary
34%
Heart
26%
Gene Interaction Network
Click a node to explore
PRKAB1CAB39TSC1ACACAACACBELAVL1GYS1
PROTEIN STRUCTURE
Preparing viewer…
PDB8BIK · 2.50 Å · X-ray
View on RCSB ↗
Constraintⓘ
LOEUFⓘ
0.76LoF Tolerant
pLIⓘ
0.01Tolerant
Observed/Expected LoF0.50 [0.34–0.76]
RankingsWhere PRKAB1 stands among ~20K protein-coding genes
  • #2,128of 20,598
    Most Researched199 · top quartile
  • #866of 1,025
    FDA-Approved Drug Targets1
  • #6,038of 17,882
    Most Constrained (LOEUF)0.76
Genes detectedPRKAB1
Sources retrieved25 papers
Response time—
📄 Sources
25▼
1
Oxidative stress gene expression, DNA methylation, and gut microbiota interaction trigger Crohn's disease: a multi-omics Mendelian randomization study.
PMID: 37170220
BMC Med · 2023
1.00
2
Buddleoside alleviates nonalcoholic steatohepatitis by targeting the AMPK-TFEB signaling pathway.
PMID: 39936600
Autophagy · 2025
0.90
3
Schisanhenol ameliorates non-alcoholic fatty liver disease
PMID: 39309511
Acta Pharm Sin B · 2024
0.80
4
Artificial intelligence guided discovery of a barrier-protective therapy in inflammatory bowel disease.
PMID: 34253728
Nat Commun · 2021
0.70
5
Anti-diabetic drug target perturbation modulates susceptibility to aortic aneurysm.
PMID: 41265617
Eur J Pharmacol · 2025
0.68